Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 ...Middle East

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m. ET Today SAN...

Hence then, the article about viking therapeutics announces results from phase 1 clinical trial of oral tablet formulation of dual glp 1 gip receptor agonist vk2735 was published today ( Tuesday 26/03/2024 - 02:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 )

Also on site :

• Trump administration, MAGA allies spread misinformation on Pretti killing
• 2000s Post-Hardcore Band Announces Update on 'Last Ever' Show in Brooklyn Venue
• Israeli settlers chase Palestinian school bus in occupied West Bank